generalised myasthenia gravis

News

J&J's Imaavy has become the first FcRn blocker to be approved in the EU for both adolescent and adult patients with generalised myasthenia gravis.

News

AstraZeneca's gefurulimab could give gMG patients the first treatment option that they can self-administer at home once a week.

News

Regeneron could be just a few months away from filing for a myasthenia gravis drug that can be dosed just once every three months.

News

New data could expand the label of argenx's Vyvgart to include AChR-Ab seronegative patients, ~20% of gMG patients whose current options are limited.

News

Alexion has announced high-level positive results from a phase 3 trial of gefurulimab, a once-weekly self-administered treatment for gMG.